Search Results - "Sachs, Zohar"

Machine learning analysis of gene expression reveals TP53 Mutant-like AML with wild type TP53 and poor prognosis by Lee, Yoonkyu, Baughn, Linda B., Myers, Chad L., Sachs, Zohar

Get full text

Proliferation and Self-Renewal Are Differentially Sensitive to NRASG12V Oncogene Levels in an Acute Myeloid Leukemia Cell Line by Kurata, Morito, Antony, Marie Lue, Noble-Orcutt, Klara E, Rathe, Susan K, Lee, Yoonkyu, Furuno, Hidehiro, Ishibashi, Sachiko, Ikeda, Masumi, Yamamoto, Kouhei, Kitagawa, Masanobu, Largaespada, David A, Sachs, Zohar

“…NRAS proteins are central regulators of proliferation, survival, and self-renewal in leukemia. Previous work demonstrated that the effects of oncogenic NRAS in…”
Get full text

310 Mechanisms of progression of myelodysplastic syndrome to fatal secondary acute myeloid leukemia by Chang, Daniel, Noble-Orcutt, Klara, Lue Antony, Marie, Largaespada, David, Myers, Chad, Sachs, Zohar

“…OBJECTIVES/GOALS: Aim 1: Define the genetic events that cooperate with Trp53 mutations to mediate the transformation of MDS to sAML at the stem cell level. Aim…”
Get full text

Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis by Pitel, Beth A., Sharma, Neeraj, Zepeda-Mendoza, Cinthya, Smadbeck, James B., Pearce, Kathryn E., Cook, Joselle M., Vasmatzis, George, Sachs, Zohar, Kanagal-Shamanna, Rashmi, Viswanatha, David, Xiao, Sheng, Jenkins, Robert B., Xu, Xinjie, Hoppman, Nicole L., Ketterling, Rhett P., Peterson, Jess F., Greipp, Patricia T., Baughn, Linda B.

Get full text

Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect by Liegel, Jessica, Courville, Elizabeth, Sachs, Zohar, Ustun, Celalettin

Get full text

Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry by Baughn, Linda B., Sachs, Zohar, Noble-Orcutt, Klara E., Mitra, Amit, Van Ness, Brian G., Linden, Michael A.

“…Multiple myeloma (MM) is an incurable malignant plasma cell neoplasm. Proteasome inhibitors including Bortezomib (Bz) are used to treat MM, and treatment…”
Get full text

Identification of NRAS Downstream Genes with CRISPR Activation Screening by Tatsumi, Akiya, Hirakochi, Haruka, Inoue, Satomi, Tanaka, Yosuke, Furuno, Hidehiro, Ikeda, Masumi, Ishibashi, Sachiko, Taguchi, Towako, Yamamoto, Kouhei, Onishi, Iichiroh, Sachs, Zohar, Largaespada, David A., Kitagawa, Masanobu, Kurata, Morito

“…Mutations in NRAS constitutively activate cell proliferation signaling in malignant neoplasms, such as leukemia and melanoma, and the clarification of…”
Get full text

Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma by Baughn, Linda B., Jessen, Erik, Sharma, Neeraj, Tang, Hongwei, Smadbeck, James B., Long, Mark D., Pearce, Kathryn, Smith, Matthew, Dasari, Surendra, Sachs, Zohar, Linden, Michael A., Cook, Joselle, Keith Stewart, A., Chesi, Marta, Mitra, Amit, Leif Bergsagel, P., Van Ness, Brian, Kumar, Shaji K.

“…Multiple myeloma (MM) remains an incurable plasma cell (PC) malignancy. Although it is known that MM tumor cells display extensive intratumoral genetic…”
Get full text

Prospective evaluation of genome sequencing to compare conventional cytogenetics in acute myeloid leukemia by Pitel, Beth A., Zepeda-Mendoza, Cinthya, Sachs, Zohar, Tang, Hongwei, Shivaram, Suganti, Sharma, Neeraj, Smadbeck, James B., Smoley, Stephanie A., Pearce, Kathryn E., Luoma, Ivy M., Cook, Joselle, Litzow, Mark R., Hoppman, Nicole L., Viswanatha, David, Xu, Xinjie, Ketterling, Rhett P., Greipp, Patricia T., Peterson, Jess F., Baughn, Linda B.

Get full text

Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency by Sachs, Zohar, Been, Raha A, DeCoursin, Krista J, Nguyen, Hanh T, Mohd Hassan, Nurul A, Noble-Orcutt, Klara E, Eckfeldt, Craig E, Pomeroy, Emily J, Diaz-Flores, Ernesto, Geurts, Jennifer L, Diers, Miechaleen D, Hasz, Diane E, Morgan, Kelly J, MacMillan, Margaret L, Shannon, Kevin M, Largaespada, David A, Wiesner, Stephen M

“…Juvenile myelomonocytic leukemia is a rare myeloproliferative neoplasm characterized by hyperactive RAS signaling. Neurofibromin1 (encoded by the NF1 gene) is…”
Get full text

Buccal epithelial cells display somatic, bone marrow–derived CALR mutation by Gilles, Scott R., Baughn, Linda B., Schomaker, Matthew L., Courville, Elizabeth L., Nelson, Andrew C., Sachs, Zohar

“…•Buccal epithelial cells harbor an MPN-associated CALR mutation in a patient with CALR-mutant essential thrombocytosis, Ph+ CML, and no germ line CALR mutation…”
Get full text

Gene Expression Analysis Reveals a Subset of TP53mutant-like AML with Wild Type TP53 and Poor Prognosis by Lee, Yoonkyu, Myers, Chad, Sachs, Zohar

Get full text

Novel single-cell technologies in acute myeloid leukemia research by Gupta, Soumyasri Das, Sachs, Zohar

“…Acute myeloid leukemia (AML) is a lethal malignancy because patients who initially respond to chemotherapy eventually relapse with treatment refractory…”
Get full text

Lymphomatous Infiltration of the Kidney in a Patient with Waldenstrom Macroglobulinemia: PO1912 by Ravipati, Prasanth, Bu, Lihong, Sachs, Zohar, Nachman, Patrick H.

Get full text

Single Cell Correlation Analysis: A Novel Method to Analyze Single Cell RNA Sequencing Data Identifies a Self-Renewing Subpopulation of Human Acute Myeloid Leukemia Stem Cells by Lee, Yoonkyu, Wang, Wen, Starr, Timothy K, Noble-Orcutt, Klara E, Myers, Chad L, Sachs, Zohar

“…Introduction Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy. Despite early response to standard chemotherapy, 60-70% of patients…”
Get full text

TP53 Altered Acute Myeloid Leukemia Stem Cells Hyperactivate Nuclear Factor-Kappa B by Antony, Marie Lue, Noble-Orcutt, Klara E, Jensen, Jeffrey Lee, He, Fiona, Sachs, Zohar

Get full text

TP53-Mutated Acute Myeloid Leukemia Patients Treated with Intensive Therapies Have Superior Outcomes: A Single Institution, Retrospective Study by Sumransub, Nuttavut, Steinwand, Gabriel K, Lee, Yoonkyu, Cao, Qing, Allred, Jeremy R., Ramesh, Vidhyalakshmi, Myers, Chad L, Sachs, Zohar

“…Background: Mutations in TP53, found in 5-20% of acute myeloid leukemia (AML), confer poor prognosis and are associated with high rates of therapy resistance,…”
Get full text

Proteasome Inhibition Attenuates Self-Renewal in Human Acute Myeloid Leukemia By Targeting NF-Kappa B in Leukemia Stem Cells by Antony, Marie Lue, Noble-Orcutt, Klara, Jensen, Jeffrey Lee, He, Fiona, Sachs, Zohar

“…In acute myeloid leukemia (AML), relapse following standard chemotherapy is common, leading to 2-year survival rates of less than 30%. Relapse is caused by…”
Get full text

p16Ink4a Interferes with Abelson Virus Transformation by Enhancing Apoptosis by SACHS, Zohar, SHARPLESS, Norman E, DEPINHO, Ronald A, ROSENBERG, Naomi

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Therapeutic Vulnerabilities in Acute Myeloid Leukemia (AML) with TP53 Alterations by Ogunsan, Oluwateniayo, Antony, Marie Lue, Noble-Orcutt, Klara E., He, Fiona, Sachs, Zohar

“…Abstract only Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow with a low two‐year survival rate. Standard chemotherapy achieves complete…”
Get full text